08/15/2026
Is this TRUE??? Universal Health Coverage Could Save $1 Trillion and 114,000 Lives Every Year, Yale Study Projects. Is that Yale study claiming Medicare for All would save $1 trillion and 114,000 lives every year true?
No. Itās a non-peer-reviewed preprint built on highly optimistic assumptions ā massive drug-price cuts, admin costs dropping to ~2%, all providers paid at Medicare rates, big fraud reductions, etc.
Independent analyses (CBO, Urban Institute, others) paint a different picture:
ā¢ Huge shift of private premiums onto taxes (federal costs often projected $1.5ā3T+ higher per year)
ā¢ Increased demand outrunning supply ā longer waits and rationing risks (common in many single-payer systems)
ā¢ Provider rate cuts that can shrink capacity and access
Coverage expansion can save lives and reduce certain waste. But static models that ignore behavioral responses, transition costs, and political realities tend to overstate the free lunch. The fine print matters. FULL FACTS: No, the claim is not established fact. It is a projection from a July 2026 preprint (not peer-reviewed) by researchers including Alison Galvani at Yale School of Public Health. The model estimates ~$1.04 trillion lower national health expenditures and ~114,000 fewer deaths annually under a Medicare for All-style single-payer system, using 2024 data.
The authors identify savings mainly from:
ā¢ Lower drug prices (large assumed cuts, often via international reference pricing).
ā¢ Paying providers at Medicare rates (well below typical commercial rates).
ā¢ Sharp reductions in administrative overhead (to roughly Medicareās ~2% level).
ā¢ Reduced fraudulent billing.
ā¢ Fewer avoidable emergency/hospital visits.
They also factor in extra spending for previously unmet needs, unpaid care, and dental coverage. A more conservative scenario in the same work still projects hundreds of billions in net savings. Galvani previously advised informally on related legislation, and the work updates their earlier (peer-reviewed) 2020 Lancet analysis that projected smaller savings (~$450 billion and ~68,000 lives).
Why independent analyses diverge
Other reputable modeling (Congressional Budget Office, Urban Institute, Mercatus Center, and others) typically finds:
ā¢ Large increases in federal (taxpayer-financed) spending ā often in the range of $1.5ā3+ trillion per year or $25ā35+ trillion over a decade ā because private premiums, employer contributions, and out-of-pocket costs shift onto the federal budget. National spending can be projected as flat, modestly lower, or higher depending on assumptions about payment rates and utilization.
ā¢ Induced demand (people using more care once cost barriers disappear) plus supply constraints often offset or exceed administrative and price savings.
ā¢ Provider payment cuts to Medicare levels risk reduced capacity, especially for specialists or in certain markets, because many providers currently rely on higher commercial rates to cover costs.
Mortality benefits from coverage expansion are real but debated in magnitude. Observational comparisons of insured vs. uninsured often overstate effects relative to stronger evidence (e.g., the Oregon Medicaid experiment). The preprintās inclusion of large underinsured and recent-policy effects adds uncertainty.
In short, the Yale numbers rely on highly favorable simultaneous assumptions about achievable savings. Strip or moderate the most contestable ones (drug prices, fraud, admin, full Medicare-rate feasibility), and the net national savings shrink substantially or disappear. Preprints are useful for discussion but are not settled science.
Expected costs, trade-offs, and āunforeseenā issues if enacted
A single-payer system would not magically make care free or eliminate scarcity. Major expected consequences include:
ā¢ Large tax increases (or equivalent revenue measures). Even if total national spending falls, the financing shifts heavily to taxes. Independent estimates have illustrated needs on the order of a 25ā32% payroll tax, large income surtaxes, a high VAT, or combinations thereof to replace private premiums. Distributional effects matter: many middle-income households currently covered by employer plans could face higher net costs once taxes replace premiums, while lower-income and currently uninsured groups gain. Transition chaos (job losses in insurance administration, renegotiating provider contracts, systems overhaul) would add short-to-medium-term costs not fully captured in static models.
ā¢ Increased demand meeting constrained supply ā waits, rationing, or denials. Eliminating deductibles/copays and expanding coverage raises utilization. CBO and others note that demand growth typically outpaces supply growth (even after administrative time savings free up some clinician hours). Result: longer waits for elective procedures, specialist appointments, imaging, or non-urgent careāpatterns already visible in many single-payer systems abroad (e.g., UK, Canada). Explicit rationing can occur via queues, prior-authorization equivalents, formulary restrictions, or capacity limits rather than price. Emergency and primary care might improve for the previously uninsured, but overall access is not guaranteed to rise uniformly.
ā¢ Provider responses and capacity risks. Steep rate cuts can lead some physicians/hospitals to reduce hours, exit certain markets, consolidate, or shift toward cash-pay/concierge models where allowed. Rural and safety-net providers are especially vulnerable. Innovation incentives (especially for new drugs/devices) could weaken under aggressive price controls.
ā¢ Other real-world frictions. Fraud does not vanish under public systems (Medicare already has substantial improper payments). Political pressure can expand benefits over time, eroding savings. Administrative simplification is real but incompleteāutilization management, quality measurement, and appeals processes still require bureaucracy. Transition costs, workforce disruption, and potential short-term disruptions to care continuity are routinely under-modeled.
International single-payer experiences show universal coverage is achievable and can deliver good population health outcomes with lower per-capita spending, but they routinely feature waits for non-emergency care, capacity constraints, and trade-offs between access and cost control. The U.S. starts from a higher-cost, higher-capacity baseline with different demographics, malpractice environment, and expectations, so direct transplantation is imperfect.
Bottom line: The Yale preprint presents an optimistic scenario under specific assumptions. Broader evidence indicates that while administrative waste and high prices are genuine problems, a pure Medicare for All transition would involve massive federal financing shifts (i.e., tax increases for many), higher utilization pressure, and real risks of longer waits or constrained access in parts of the system. Static models rarely capture dynamic behavioral responses, political economy, or transition frictions fully. Policy debate should weigh those trade-offs against the status quoās own inefficiencies and coverage gaps rather than treat any single projection as definitive.
